Premium
Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP‐9
Author(s) -
Buggins Andrea G. S.,
Levi Ana,
Gohil Satyen,
Fishlock Keith,
Patten Piers E. M.,
Calle Yolanda,
Yallop Deborah,
Devereux Stephen
Publication year - 2011
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2011.08725.x
Subject(s) - cd44 , cd38 , mmp9 , matrix metalloproteinase , cancer research , pathology , medicine , cell , biology , chemistry , immunology , microbiology and biotechnology , downregulation and upregulation , biochemistry , stem cell , gene , cd34
Summary Progressive chronic lymphocytic leukaemia is characterized by the accumulation of neoplastic B‐cells in the tissues and correlates with the expression of prognostic biomarkers, such as CD38, CD49d and matrix metalloproteinase‐9 (MMP9), which are involved in migration and tissue invasion. In this study we investigated the physical relationship between these molecules and demonstrated that CD38, CD49d, MMP9 and CD44 were physically associated in a supramolecular cell surface complex. Our findings provide a molecular basis for the correlation between expression of these proteins and prognosis and, as the complex is not present in normal B‐cells, suggest a novel leukaemia‐specific therapeutic target.